as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹22.09
Change
+0.01 (0.05%)
Open
₹22.08
Prev. Close
₹22.08
Day High
₹22.35
Day Low
₹21.51
Volume Analysis
Traded
15,186,461
Delivered
3,555,701
Delivery %
23.41%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (20.0%)
Weaknesses (0)
No signal for this stock
Opportunities (3)
- •Strong 3-year EPS growth (56.8%)
- •Strong 3-year revenue growth (30.0%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹23.29 | ₹22.82 | ₹22.45 | ₹21.98 | ₹21.61 | ₹21.14 | ₹20.77 |
| Fibonacci | ₹22.82 | ₹22.5 | ₹22.3 | ₹21.98 | ₹21.66 | ₹21.46 | ₹21.14 |
| Camarilla | ₹22.32 | ₹22.24 | ₹22.17 | ₹21.98 | ₹22.01 | ₹21.94 | ₹21.86 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+56.89%
1 Week
+9.14%
1 Month
+0.09%
3 Months
+36.86%
6 Months
+54.04%
1 Year
+38.06%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹9.55
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.22%
Net margin 18.53% × asset turnover 0.85x × equity multiplier 1.22x
Company Overview
Sector
Healthcare
Market Cap
₹1,907 Cr
P/E (TTM)
20.0
ROE
17.6%
Book Value
₹5.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Syncom Formu (i) Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 73/100. The strongest factor is Financial Strength (100/100), while Risk & Volatility (48/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (20.0%). Strong 3-year EPS growth (56.8%).
TopFund Score — Fundamentals Quality
73/100 — GoodData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Debtor days have improved from 104 to 82.6 days.
- −Earnings include an other income of Rs.34.0 Cr.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Submission of Press Clipping regarding publication of extract of Unaudited Standalone and Consolidated Financial Results for the Quarter/Half Year ended on 30th September, 2026
Syncom Formulations posted Q2 FY27 unaudited standalone and consolidated results on 13 November 2026.
Certificate for Compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th September, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 64 | 65 | 75 | 87 | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 | 142 |
| Expenses + | 57 | 58 | 65 | 77 | 90 | 113 | 131 | 101 | 103 | 94 | 113 | 99 | 110 |
| Operating Profit | 6 | 7 | 9 | 10 | 12 | 15 | 18 | 16 | 18 | 21 | 22 | 26 | 32 |
| OPM % | 10.0% | 11.0% | 13.0% | 12.0% | 12.0% | 12.0% | 12.0% | 14.0% | 15.0% | 18.0% | 16.0% | 21.0% | 22.0% |
| Other Income + | 4 | 5 | 3 | 1 | 4 | 4 | 7 | 6 | 5 | 6 | 15 | 8 | 6 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 |
| Profit before tax | 8 | 9 | 10 | 10 | 15 | 17 | 23 | 20 | 22 | 25 | 34 | 32 | 36 |
| Tax % | 23.0% | 25.0% | 26.0% | 24.0% | 25.0% | 25.0% | 24.0% | 22.0% | 25.0% | 25.0% | 25.0% | 23.0% | 26.0% |
| Net Profit + | 7 | 7 | 7 | 8 | 11 | 13 | 18 | 16 | 17 | 19 | 25 | 25 | 27 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 17 | 14 | 22 | 46 | 60 | 96 | 100 | 34 | 19 | -10 | -9 | 7 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 115 | 151 | 173 | 184 | 185 | 216 | 222 | 262 | 463 | 488 | 518 |
| Expenses + | 104 | 135 | 155 | 167 | 168 | 196 | 202 | 232 | 408 | 411 | 417 |
| Operating Profit | 11 | 16 | 18 | 17 | 17 | 20 | 20 | 30 | 54 | 77 | 101 |
| OPM % | 9.0% | 11.0% | 11.0% | 9.0% | 9.0% | 9.0% | 9.0% | 11.0% | 12.0% | 16.0% | 20.0% |
| Other Income + | 1 | 1 | 1 | 3 | 3 | 12 | 15 | 14 | 17 | 31 | 34 |
| Interest | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 5 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 5 | 7 | 7 |
| Profit before tax | 8 | 14 | 16 | 16 | 16 | 26 | 27 | 34 | 66 | 101 | 127 |
| Tax % | 33.0% | 33.0% | 38.0% | 36.0% | 34.0% | 24.0% | 24.0% | 25.0% | 25.0% | 24.0% | — |
| Net Profit + | 6 | 9 | 10 | 10 | 11 | 20 | 20 | 25 | 49 | 76 | 96 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Dividend Payout % | 24.0% | 17.0% | 16.0% | 15.0% | 15.0% | 13.0% | 0.0% | 0.0% | 0.0% | 12.0% | — |
| Sales growth | — | 32 | 15 | 6 | 0 | — | 3 | 18 | 77 | 5 | 1 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 65 | 17 | 22 | 31 | 39 | 136 | 162 | 194 | 248 | 321 | 376 |
| Borrowings + | 2 | 3 | 6 | 6 | 12 | 58 | 83 | 72 | 5 | 1 | 16 |
| Other Liabilities + | 33 | 42 | 31 | 61 | 50 | 28 | 39 | 44 | 67 | 117 | 87 |
| Total Liabilities | 123 | 140 | 138 | 175 | 180 | 308 | 378 | 405 | 413 | 534 | 573 |
| Fixed Assets + | 50 | 50 | 46 | 46 | 55 | 94 | 91 | 120 | 125 | 184 | 182 |
| CWIP | 0 | 0 | 0 | 5 | 0 | 6 | 26 | 0 | 0 | 0 | 4 |
| Investments | 7 | 9 | 6 | 23 | 36 | 43 | 64 | 66 | 93 | 109 | 174 |
| Other Assets + | 66 | 80 | 85 | 101 | 89 | 165 | 197 | 219 | 196 | 241 | 214 |
| Total Assets | 123 | 140 | 138 | 175 | 180 | 308 | 378 | 405 | 413 | 534 | 573 |
| Equity Capital | 22 | 78 | 78 | 78 | 78 | 86 | 94 | 94 | 94 | 94 | 94 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 6 | 7 | 0 | 24 | 14 | 16 | 11 | -6 | 23 | 58 |
| Cash from Investing Activity + | 0 | -4 | 1 | -23 | -18 | -27 | -45 | 83 | -18 | -51 |
| Cash from Financing Activity + | -6 | -1 | 1 | -2 | 5 | 8 | 35 | -15 | -68 | -3 |
| Net Cash Flow | -1 | 2 | 2 | -1 | 1 | -2 | 1 | 62 | -63 | 4 |
| Free Cash Flow | 3 | 4 | -3 | 21 | 2 | 5 | -10 | -14 | 13 | 46 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 76 | 66 | 32 | 176 | 108 | 113 | 86 | 7 | 70 | 105 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 49.44% | 49.35% | 49.34% | 49.34% | 49.3% | 49.32% | 49.02% | 49.33% | 49.17% | 49.23% | 49.07% | 47.2% |
| Promoters | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% | 50.57% |
| FII | 0.0% | 0.08% | 0.09% | 0.1% | 0.13% | 0.11% | 0.41% | 0.1% | 0.26% | 0.21% | 0.35% | 2.23% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Syncom Formu (i) Ltd (this stock) | 1,907 | 20.0 | 4.06 | 17.6% |
| Beta Drugs Limited | 1,990 | 38.3 | 4.54 | 18.8% |
| Hester Biosciences Ltd | 1,992 | 33.9 | 4.26 | 15.9% |
| Venus Remedies Limited | 2,002 | 16.4 | 2.84 | 15.6% |
| Ngl Fine Chem Limited | 1,783 | 27.9 | 4.92 | 17.4% |
| Suraksha Diagnostic Ltd | 1,780 | 42.6 | 6.45 | 14.2% |
| Windlas Biotech Limited | 2,067 | 31.1 | 3.64 | 12.2% |
Which Mutual Funds Hold Syncom Formu (i) Ltd?
Frequently Asked Questions about Syncom Formu (i) Ltd
Syncom Formu (i) Ltd (SYNCOMF) closed at ₹22.09 on NSE on 19 November 2026, up 0.01 (0.05%) from the previous close.
Syncom Formu (i) Ltd trades on the NSE (National Stock Exchange of India) under the symbol SYNCOMF.
Syncom Formu (i) Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 20.0.
Syncom Formu (i) Ltd has a dividend yield of 0.49%.
Syncom Formu (i) Ltd's 52-week high is ₹27.5 and its 52-week low is ₹10.2.
Syncom Formu (i) Ltd has a market capitalisation of ₹1,907 crore.
Syncom Formu (i) Ltd has a TopFund Quality Score of 73/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Syncom Formu (i) Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.